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Summary
Objective: This preliminary study sought to determine whether using 1500/1200 mg of glucosamine hydrochloride and chondroitin sulfate (GH/
CS) is effective, both separately and combined with exercise, compared to a placebo plus exercise program in improving physical function,
pain, strength, balance, and mobility in older adults with knee osteoarthritis (OA).
Methods: This double-blind, placebo-controlled, randomized clinical trial lasted 12 months. Participants included 89 older adults (age 50
years) with knee OA randomized to either GH/CS or placebo group. Phase I was a 6-month trial comparing the effects of assignment to either
GH/CS or placebo. Phase II added 6 months of exercise for both groups. The primary outcome measure was Western Ontario and McMaster
University Osteoarthritis Index (WOMAC) function, and secondary outcome measures included WOMAC pain, 6-min walk, balance, and knee
strength.
Results: Of the 89 randomized participants, 72 (81%) completed the study. The median pill compliance was 94% and 95% in Phase I, and, in
Phase II, 97% and 91% for the GH/CS and placebo groups, respectively. Median exercise compliance during Phase II was 77% for the GH/CS
group and 78% for the placebo group. WOMAC function and pain did not differ signiﬁcantly between the groups at 6- or 12-month follow-up.
There were also no signiﬁcant differences between the groups in 6-min walk or knee strength; however, balance was better in the placebo
group with approximately a 10% difference compared to the GH/CS group.
Conclusions: The GH/CS group was not superior to the placebo group in function, pain, or mobility after both phases of the intervention (pill
only and pill plus exercise).
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Recently, osteoarthritis (OA) treatment using glucosamine
and chondroitin has gained widespread use. Classiﬁed as
prescription drugs in continental Europe, glucosamine and
chondroitin are less regulated dietary supplements in the
United States and Great Britain. Several studies have
shown that glucosamine sulfate was effective in reducing
pain and other OA symptoms compared to a placebo1e3.
In contrast, Rindone et al.4 found no difference in knee
pain between glucosamine sulfate and a placebo. The re-
sults of several meta-analyses suggest that the effect of glu-
cosamine sulfate ranges from a modest, short-term effect
on pain to structural efﬁcacy5e8. McAlindon et al.6 noted
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Received 20 June 2006; revision accepted 9 April 2007.12that the available studies had design and data analysis
ﬂaws, including small number of participants, small treatment
effects, short duration, publication bias, selective publication
of positive trials, unaccounted-for use of concomitant pain
medications, and lack of intent-to-treat analysis.
In a more recent meta-analysis, Richy et al.5 concluded
that 1500 mg of glucosamine sulfate taken for 3 years slows
the degenerative process. This conclusion was based pri-
marily on the strength of two long-term randomized clinical
trials that showed signiﬁcant improvements in self-reported
physical function and signiﬁcantly less OA knee disease
progression after 3 years of treatment2,9. Preliminary data
from the glucosamine unum in die efﬁcacy (GUIDE) trial
performed in Europe found patients using glucosamine sul-
fate for 6 months had signiﬁcantly less knee pain than a pla-
cebo3. Recent evidence from the glucosamine/chondroitin
arthritis intervention trial (GAIT), a Phase III clinical trial,
found no difference in overall Western Ontario and McMas-
ter University Osteoarthritis Index (WOMAC) pain scores
after 24 weeks of receiving either glucosamine hydrochlo-
ride (GH), chondroitin sulfate (CS), glucosamine plus56
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review concluded that clinical trials using the Rotta Pharma-
ceutical preparation of glucosamine sulfate were more
effective than studies using other glucosamine sulfate for-
mulas; however, the results were not uniformly positive7.
Some people have suggested that a combination of glu-
cosamine and CS is efﬁcacious in OA. Two studies reported
that a combination of glucosamine, chondroitin, and manga-
nese ascorbate signiﬁcantly improved pain in adults with
knee OA11,12. Similarly, a combination therapy that included
glucosamine, chondroitin, and vitamin C improved temporo-
mandibular joint pain in 40 out of 50 participants13. Second-
ary results from the GAIT trial found a beneﬁcial effect in the
combination of glucosamine and chondroitin, however, only
in participants with moderate to severe pain10. Taken to-
gether, these data suggest that glucosamine and chondroitin
have beneﬁcial effects (effect sizes 0.44 and 0.78 for glucos-
amine and chondroitin, respectively) on joint pain from OA14.
Exercise is a proven non-pharmacologic treatment for knee
OA15. It results in clinically signiﬁcant improvements in function,
pain, and strength and does not exacerbate disease progres-
sion15e19. We hypothesized that the effects of glucosamine hy-
drochloride and chondroitin sulfate (GH/CS) therapy combined
with exercise would be additive, resulting in greater improve-
ments in function, pain, and mobility than exercise alone. We
proposed a two-phase, short-term, preliminary study in older
adults with knee OA to compare the effects of GH plus CS to
a placebo (Phase I) on function, pain, mobility, strength, and
balance, and the added effects of exercise therapy (Phase II).
Patients and methods
DESIGN
The glucosamine/chondroitin and training exercise study
(GATES) was a 12-month, double-blind, placebo-controlled,
randomized clinical trial (RCT) of older adults with knee OA.
Phase I was a 6-month trial designed to compare the effects
of assignment to either a combination of GH/CS or a pla-
cebo. Phase II added identical 6-month exercise programs
for both groups. The study was conducted at the Wake For-
est University Clinical Research Center with the approval of
the University’s Institutional Review Board.
PARTICIPANT RECRUITMENT
Recruitment techniques included phone calls and mail-
ings to participants in previous knee OA clinical trials who
had provided consent for notiﬁcation of future trials; adver-
tisements in local newspapers; and informational sessions
at senior centers, assisted-living facilities, and local
churches. Recruitment was open to people aged 50 years
with radiographic evidence of mild to moderate knee OA
(KellgreneLawrence grade IIeIII20) who met the American
College of Theumatology (ACR) classiﬁcation criteria21. Re-
cruitment speciﬁcally targeted minority groups by placing
ads in a local minority newspaper and sending letters an-
nouncing the trial to minority churches. Dates for recruit-
ment were August 2002eDecember 2003. Recruitment
waves began every 3 months and follow-up at 6 (FU6)
and 12 (FU12) months. The study ended in December 2004.
INCLUSION/EXCLUSION CRITERIA
Inclusion criteria included age 50 years with radiographic
evidence of mild to moderate knee OA (KellgreneLawrencegrade IIeIII20) who met the ACR clinical21, and radiographic
classiﬁcation criteria or conﬁrmation of mild to moderate radio-
graphicevidenceofkneeOAfromapersonalphysician;andnot
currently participating in another intervention study. Exclusion
criteria included dementia (Mini-Mental State Examination
[MMSE]< 24); active cancer other than skin cancer; anemia
(participants with an hematocrit (HCT)< 32 (or a hemoglobin
below 10)were excluded due to possible inability to adequately
exercise or the increased potential for increased risk for serious
adverse cardiovascular events); severe renal insufﬁciency (se-
rum creat> 2); hepatic disease (the effects of hepatic disease
on the response to exercise or GH/CS that are metabolized in
the liver are not well known); excess alcohol use (21 alcoholic
drinks perweek); knee-joint replacement, inability towalk unas-
sistedat least128 min6 min; completionofmore than20 minof
formal exercise per week during the past 3 months; planned
absence for longer than2weeksduring requiredstudyvisits; re-
siding farther than a 1-h drive from the research facilities; inabil-
ity to swallow a test pill; allergy to shellﬁsh; exposure to
glucosamine and/or chondroitin in the 6 months prior to ran-
domization; unwilling to discontinue current arthritis medica-
tions during the 2-week washout period and 12-month
intervention period, with the exception of a rescue medication;
less than 80% compliance rate during run-in period (see Mea-
surements and procedures); failure to complete graded exer-
cise test (GXT); required human assistance with activities
related to knee pain (e.g., walking up and down stairs; getting
in or out of a chair, etc.); recent knee surgeries, or knee injec-
tions such as cortisone and hyaluronic acid; and inability to
read or speak English.
Interventions
PHASE I: GH/CS VS PLACEBO
Run-in/washout period
Prior to randomization, participants underwent a 2-week
run-in, washout period; that is, they discontinued all over-
the-counter or prescription medications. These medications
and the number of patients using them at baseline were
non-steroidal anti-inﬂammatory drugs (NSAIDs): 16, 18;
acetaminophen: 46, 37; aspirin: 25, 26; narcotic: 4, 1; and
migraine analgesic: 5, 3 for the treatment and placebo
groups, respectively. Rescue medication (acetaminophen:
maximum dosage 4 g d1) and any other necessary medi-
cations unrelated to OA were permitted. All participants re-
ceived an unblinded 2-week supply of the placebo (three
pills per day). At the end of the 2-week period, the bottles
were returned to the study staff. Pill compliance was calcu-
lated as the number of pills taken/number prescribed.
A compliance rate below 80% was an exclusion criterion.
Phase I
After the run-in/washout period, participants were random-
ized to either a glucosamine/chondroitin group or a placebo
control group. The glucosamine/chondroitin group was treated
with 1500/1200 mg of unlabeled GH/CS per day for 6 months.
The participants were given a choice of either once or three
times per day regimens. The control group took a placebo
of identical size, color, and shape at the same frequency.
Both groups attended six healthy lifestyle classes on such
topics as living with OA, healthy eating, and exercise, de-
signed to keep participants interested and involved in the
study until the beginning of Phase II. Each participant also
met monthly with a research interventionist to monitor study
compound and rescue medication use (pill counts), to review
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opportunity to voice questions or concerns that they might
not have felt comfortable addressing in group sessions. At
the end of Phase I, participants repeated the series of tests
conducted at baseline. Each participant began Phase II after
the 6-month follow-up testing was completed.
PHASE II: GH/CS PLUS EXERCISE VS PLACEBO PLUS
EXERCISE
Phase II was a continuation of Phase I intervention with the
addition of 6 months of exercise for both groups. The
combined facility and home-based exercise program was
modeled after our large-scale OA clinical trials, ﬁtness arthri-
tis in seniors trial (FAST) and arthritis diet and activity promo-
tion trial (ADAPT)15,22. Facility-based exercise classes were
held 2 d week1, 1 h d1. Each participant supplemented the
facility-based sessions with one home-based session per
week. Sessions began and ended with 5-min warm-up and
cool-down periods, respectively. The exercise phase in-
cluded two 15-min walking sessions separated by 20 min
of strength training. Participants were provided with an aero-
bic exercise prescription that included walking within a heart-
rate range of 50e75% of heart-rate reserve. Each strength
training session consisted of 10e12 repetitions of the follow-
ing exercises: (1) leg extension, (2) leg curl, (3) heel raise,
and (4) step up. Cuff weights and machines provided resis-
tance. Following two orientation sessions, participants
began with the lowest possible resistance. Weight was in-
creased in 2.5e5 lb increments, depending on the partici-
pant, after two sets of 12 repetitions had been performed
for 2 consecutive days. A 1e1.5 min rest interval separated
each exercise. American College of Sports Medicine-
certiﬁed Exercise Leaders supervised each session, and ex-
ercise and attendance logs were used to monitor progress.
The home-based exercise mirrored the facility-based
sessions. Each participant met individually with one of the
Exercise Leaders to discuss exercising at home, and the
healthy lifestyle classes conducted in Phase I included in-
formation about community-based exercise programs for
seniors. If compliance to the home-based program fell be-
low expected levels, the Exercise Leader assisted the par-
ticipant in an exercise session and discussed the barriers
that the participant was encountering. Monthly individual
sessions continued during Phase II to monitor compliance
with the study supplement and exercise program.
Supplement and placebo allocation
The study sponsor (Rexall Sundown, Inc.) donated the
study compound and matching placebo. All study compound
bottles received were numbered with a corresponding sealed
list including lot numbers and bottle contents (active or pla-
cebo). The study compound was allocated in order at the ﬁrst
healthy lifestyle class. A certiﬁcate of analysis, issued and ap-
proved by the study sponsor’s quality-assurance manager
and veriﬁed by an independent source (Consumer Lab,
Inc.), revealed that each study tablet contained GH
(503.778 mg/99% glucosamine) and CS (497.388 mg/80%
chondroitin). Inactive ingredients included microcrystalline
cellulose 102 National Formulary (NF) (6.833 mg), beet pow-
der (12.310 mg), crosprovidoneUSPharmacopeia (USP)/NF
(10.258 mg), magnesium stearate Food Chemical Codex
(FCC) (5.000 mg), and precipitated silica (1.026 mg).
Rescue medication was available during the entire
course of the study. Each participant received enough500 mg tablets of acetaminophen to allow the maximum
daily dose of 4 g d1 for pain relief. During a monthly visit
with the study coordinator, participants were asked whether
they used any rescue medication in the previous month.
Participants who required pain control medication in excess
of 4 g d1 discussed an alternative plan with the study coor-
dinator and the study physician.
Measurements and procedures
Each subject participated in a series of tests at baseline
and at 6- and 12-month follow-up. Two screening visits
(SV1 and SV2) were separated by the 2-week run-in/
washout period. All staff and participants were blinded to
the supplement assignment.
OUTCOME MEASURES
Physical function
The primary outcome was WOMAC self-reported physi-
cal function measure. WOMAC uses 17 questions about
the degree of difﬁculty in performing daily living activities
(e.g., descending stairs) to assess participants’ physical
function23,24. The Likert (LK) version of the WOMAC asks
participants to indicate on a scale from 0 (none) to 4 (ex-
treme) the degree of difﬁculty they have experienced in
the last 48 h due to knee OA. Individual scores for the 17
items are added to generate a summary score that can
range from 0 to 68, with higher scores indicating poorer
function. This instrument, which also includes questions
about pain that were used as secondary outcomes, has
been validated and is recommended by the Osteoarthritis
Research Society as the measure of choice when assess-
ing health status in older adults with knee OA24.
Pain
The WOMAC pain subscale assessed a participant’s
level of pain. It consists of ﬁve items, and total scores can
range from 0 to 20, with larger scores indicating greater dys-
function. The ratings for pain are identical to the WOMAC
physical function scale, ranging from 0 (none) to 4
(extreme).
Mobility
The distance walked in 6 min was our measure of mobil-
ity25. Participants walked as far as possible in 6 min on an
established course.
MMSE
We used the MMSE to assess participants’ mental status
and to exclude those participants with a score below 2426.
Strength
We assessed knee concentric extension and ﬂexion
strength of the participant’s most affected limb using
a Kin-Com 125E isokinetic dynamometer (Chattanooga
Corp.) set at an angular velocity of at 30 s1. Prior to test-
ing, a warm-up period habituated participants to the testing
equipment. They were secured with the torso and tested leg
strapped to the testing chair, hands across the chest, the
axis of the dynamometer aligned with the knee, and the
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ankle joint. Gravity effect torque was calculated based on
the participant’s leg weight at a 45 angle.
The activation force for each muscle group was set at
50% maximal voluntary isometric contraction. Strength
was measured through a joint range from 90 to 30
(0 ¼ full extension). The ﬁrst and last 10 were subse-
quently deleted to account for the acceleration and deceler-
ation of the dynamometer at the ends of the range of motion
and to account for inconsistent effort. Hence, average force
was the average value between joint angles of 40 and
8027. There was a rest period of 30e60 s between each
trial. Two maximally reproducible trials were averaged,
and the maximum number of trials for each test was six.
Balance
Balance data were collected as participants stood on an
AMTI force platform interfaced with a six-channel ampli-
ﬁer and a microcomputer. The force platform was set to
sample data at 60 Hz. A template afﬁxed to the force plat-
form surface provided consistent foot placement for stance
positions. To control for the effects of footwear, subjects
were tested without shoes or socks. A shoulder harness
suspended from the ceiling afforded unrestricted movement
yet, in the event of total loss of balance, prevented a fall to
the ﬂoor.
Dynamic balance was deﬁned as the excursion of the
center of pressure (COP) in the anteroposterior plane dur-
ing a forward (Ymax) and then backward (Ymin) lean. Partic-
ipants were instructed to lean forward and backward as far
as possible, using only the ankle joint28,29. The COP excur-
sion is the difference in these maximum values (COP¼
YmaxYmin). These data were normalized by dividing the
COP excursion by the subject’s foot length. Participants
were advised to limit knee and trunk ﬂexion and shoulder
abduction. After one practice trial, four trials were recorded,
with the results of the last three averaged to yield a repre-
sentative dynamic balance value.
Demographics
Age, race, education, and income data were acquired by
self-report. Information concerning comorbid conditions was
based on the participant’s medical history, medication use,
and physical examination.
Statistical analysis
The trial’s primary objective was to determine the effects
of glucosamine/chondroitin and glucosamine/chondroitin
plus exercise interventions on physical function, pain, and
mobility. Primary analyses were conducted by intent-to-treat
using the last observation carried forward technique for
missing data, with participants analyzed according to their
initial assignment. All tests of hypotheses and reported
P-values were two-sided.
To compare groups, t tests were used for continuous de-
mographic or clinical data and Chi-square or Fisher’s exact
test for categorical data.
The effects of glucosamine/chondroitin at 6 months and
glucosamine/chondroitin plus exercise at 12 months post-
randomization were determined by repeated measures
analysis of covariance (ANCOVA), using SAS statistical
package. The main models included follow-up levels asthe dependent variables with group, time and their inter-
action as independent variables, and age, gender, body
mass index (BMI) and baseline levels as covariates. Sepa-
rate models were also ﬁtted for change from baseline
adjusting for age, gender, and BMI. P-values for group dif-
ferences at each time period are reported as they reﬂect
the effect of different interventions at the end of each phase
(pill only and pill plus exercise). P-values for differences
over time were obtained from models with no interaction
as none were statistically signiﬁcant. Results from these
models are reported in the text only.
Post hoc power calculations were obtained from two-
group t test of equal means with unequal n’s using nQuery
Advisor software. We had 80% power to detect an 8.2%
difference in 6-min walk distance and a 4.6 (23.1%) unit dif-
ference in mean WOMAC function between the two groups
at the end of the study.
Median, 25th and 75th percentiles were reported for pill
and exercise compliance because of skewed distributions.
Compliance was also divided into groups to examine the
effects of the interventions within each compliance group.
For each outcome, models were ﬁtted using ANCOVA,
with age, gender, BMI, and baseline levels as covariates.
Fourteen participants were not included because they drop-
ped from the study before Phase II started. For exercise
compliance, a 12-month P-value was reported as an overall
comparison between the high, middle, and low compliant
groups.
Change in rescue medication use was reported as
a change from baseline in the number of participants taking
rescue medication for each group. These data reﬂect
changes in the number of participants reporting the use of
rescue medication during the previous intervention period,
but do not reﬂect ﬂuctuations in dosage.
Results
RETENTION AND COMPLIANCE
The total number of persons prescreened via telephone
or face-to-face interview during the 16-month recruitment
period was 865 (Fig. 1). Of these, 89 were randomized,
and 776 were either ineligible or declined to participate.
Total Persons Prescreened
n = 865
Nonrandomized
(n = 776)
Ineligible = 341 Not interested = 435
Randomized 
(n = 89) 
Received Glucosamine/Chondroitin
plus Exercise
(n = 45)
Received Placebo plus Exercise 
(n = 44)
Follow-up Visits
6 mo. Phase I (n = 39)
12 mo. Phase II (n = 37)
Follow-up Visits
6 mo. Phase I (n = 36)
12 mo. Phase II (n = 35) 
Fig. 1. Progress of participants throughout the trial.
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health problems that met exclusion criteria (22%), already
taking glucosamine or chondroitin (15%), regular exercise
of more than 20 min per week (14%), and knee replacement
(12%). Of the 89 randomized participants, 72 (81%) com-
pleted the study (returned for the ﬁnal data-collection visit).
The most common reasons for withdrawal included lost
interest in the study and personal or family health issues.
Knee strength was measured on a subset of participants,
29 in the GH/CS group and 25 in the placebo group. The char-
acteristics of the randomized cohort are shown in Table I.
The GH/CS participants were signiﬁcantly younger, more
overweight, and had a higher income than the placebo
group. Consequently, age and BMI were used as covariates
in our statistical analyses. We also included gender as a
covariate as outcomes may vary between men and women.
The only reported adverse event was hair loss in one partic-
ipant in the GH/CS group.
CLINICAL OUTCOMES
WOMAC function
Mean function did not vary signiﬁcantly between groups
at 6-month (P¼ 0.52) or 12-month (P¼ 0.50) follow-up
(Table II and Fig. 2). However, mean WOMAC function
combining both groups improved signiﬁcantly over time
(P¼ 0.005). After 12 months, participants improved 4.6
units (17%) and 2.6 units (12%) on average from baseline
in the glucosamine/chondroitin group and the placebo
group.
Pain
The placebo group’s mean level of pain did not differ
signiﬁcantly from the GH/CS mean level at 6 months(P¼ 0.97) or at 12 months (P¼ 0.23), nor did pain levels
signiﬁcantly change over time for both groups combined
(P¼ 0.11).
Mobility
There was no signiﬁcant difference in 6-min walk dis-
tance between the groups at 6 months (P¼ 0.80) or 12
months (P¼ 0.91) (Table II). Both groups made small
(5e6%) gains over 12 months. The mean difference over
time when averaging both groups was statistically signiﬁ-
cant (P¼ 0.01).
Medication use
The number of participants who used acetaminophen
(our rescue medication) decreased by 28% and 21% in
the glucosamine/chondroitin and placebo groups, respec-
tively, at 6-month follow-up, and by 37% and 11% from
baseline at 12-month follow-up. There was no change in
the use of aspirin, other analgesics, or corticosteroids.
Two people in the GH/CS group and three in the placebo
group took NSAIDs during the course of the study for pain.
STRENGTH
Mean knee extension strength did not differ signiﬁcantly
between the groups at 6 months (P¼ 0.28) or 12 months
(P¼ 0.92) (Table II). The GH/CS group improved mean ex-
tension strength during the 6-month exercise program
(Phase II), making up for all but 2 N of the loss in strength
during Phase I. The placebo group gained 26% overall
from baseline after Phase II.
Mean knee ﬂexion strength tended to vary differently over
time between the groups. Mean values were not signiﬁcantly
different between the groups at 6 months (P¼ 0.95).Table I
Demographic and clinical characteristics of study participants, mean standard error or frequency (%)
Variables GH/CS group, N¼ 45 Placebo group, N¼ 44 Range P-value
Age (years) 70.0 1.28 74.1 1.32 52e95 0.03
Baseline BMI (kgm2) 30.7 0.93 27.3 0.71 16.9e49.9 0.005
Gender
Female 34 (75.6) 29 (65.9) 0.31
Male 11 (24.4) 15 (34.1)
Race
Caucasian 31 (68.9) 35 (77.3) 0.50
AfricaneAmerican 9 (20.0) 5 (11.4)
Asian/Paciﬁc Islander 3 (6.7) 1 (2.3)
Native American 2 (4.4) 3 (6.8)
Education
<12 Years 3 (6.8) 3 (7.3) 0.93
12 Years 8 (18.2) 6 (14.6)
>12 Years 33 (75.0) 32 (78.1)
Annual household income
<$15,000 2 (4.94) 6 (17.7) 0.05
$15,000e35,000 11 (24.4) 6 (17.7)
$35,000e50,000 7 (15.6) 12 (35.3)
>$50,000 21 (46.7) 10 (29.4)
Comorbidities
Cardiovascular disease 16 (35.6) 13 (29.5) 0.55
Hypertension 26 (57.8) 23 (53.3) 0.60
Cancer 8 (17.8) 6 (13.6) 0.59
Diabetes 6 (13.3) 6 (13.6) 0.97
Chronic obstructive pulmonary disease 5 (11.1) 4 (9.1) 0.99
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Between group (GH/CS vs Placebo) effects of the treatment on function, pain, 6-min walk distance, strength, and balance at FU6 and FU12.
Means (SE) adjusted for gender, age, baseline value, and BMI
Variable Group Baseline* FU6 P-value FU6 FU12 P-value FU12
Function GH/CS 25.9 (1.7) 21.9 (1.1) 0.52 19.4 (1.2) 0.50
Placebo 21.1 (1.5) 22.9 (1.1) 20.6 (1.2)
Pain GH/CS 7.1 (0.5) 6.2 (0.4) 0.97 6.0 (0.5) 0.23
Placebo 5.9 (0.5) 6.2 (0.4) 5.18 (0.5)
6-min walk (m) GH/CS 384.7 (17.6) 393.6 (8.0) 0.80 409.2 (8.7) 0.91
Placebo 398.7 (17.3) 396.5 (7.9) 410.5 (8.6)
Knee concentric extension
strength (N)
GH/CS 209.4 (31.2) 176.9 (16.3) 0.28 207.6 (14.1) 0.92
Placebo 163.9 (20.6) 202.7 (17.5) 209.7 (15.0)
Knee concentric ﬂexion
strength (N)
GH/CS 106.0 (16.1) 106.1 (7.3) 0.95 102.9 (7.7) 0.05
Placebo 83.0 (10.9) 106.7 (7.8) 124.8 (8.3)
Balance (foot length) GH/CS 0.52 (0.04) 0.523 (0.014) 0.01 0.538 (0.017) 0.05
Placebo 0.53 (0.03) 0.583 (0.017) 0.591 (0.020)
FU6, FU12: follow-up 6 and 12 months. *Theonly signiﬁcant difference between the two groups at baseline is in function (P¼ 0.04).During Phase II, knee ﬂexion strength decreased slightly in
the GH/CS group (3 N) and increased 18 N in the placebo
group. As a result, the placebo group was signiﬁcantly
(P¼ 0.05) stronger in knee ﬂexion strength at the conclusion
of the study (Table II).
BALANCE
There was a signiﬁcant difference in balance between the
groups. The placebo group had signiﬁcantly better balance
than the GH/CS group at 6 months (0.58 vs 0.53, P¼ 0.01)
and 12 months (0.59 vs 0.54, P¼ 0.05), respectively.
EFFECTS OF PILL AND EXERCISE COMPLIANCE
The median (25th percentile and 75th percentile) for pill
compliance, deﬁned as the number taken divided by the
number prescribed, was 94% (84%, 100%) and 95%
(79%, 100%) for Phase I, and 97% (80%, 100%) and
91% (71%, 99%) for Phase II for the glucosamine/chondroi-
tin and placebo groups, respectively. Corresponding num-
bers for exercise compliance during Phase II, deﬁned as
0
8
16
24
WOMAC Function
120 6 0 6 12
Time (months)
GH/CS Placebo
Fig. 2. Mean (SE) WOMAC function at baseline, and 6- and 12-
month follow-up. Individual scores on 17 items are added to gener-
ate a summary score that can range from 0 to 68. Follow-up values
are adjusted for gender, age, baseline value, and BMI. There were
no signiﬁcant differences between the groups at 6- or 12-month
follow-up.the number of sessions completed divided by the number
scheduled, were 77% (63%, 90%) for the glucosamine/
chondroitin group and 78% (61%, 95%) for the placebo
group. Tables IIIA and IIIB show compliance over the entire
study. To be considered pill-compliant overall, a participant
had to be in the top compliance group (85e100%) during
both Phase I (months 0e6) and Phase II (months 7e12)
of the study. There were no signiﬁcant differences between
the groups in pill (P¼ 0.33) or exercise (P¼ 0.62) compli-
ance (Tables IIIA and IIIB).
Function and pain
During Phase I, pill compliance had no effect on either the
GH/CS or placebo group. However, during Phase II, the
GH/CS compliant participants had signiﬁcantly less pain
than the non-compliant group (P¼ 0.02) and showed a sim-
ilar, but non-signiﬁcant trend in function (P¼ 0.06). Pill com-
pliance had no effect on the placebo group in either function
(P¼ 0.72) or pain (P¼ 0.71) at FU12 (Table IV).
The low exercise-compliant placebo group had signiﬁ-
cantly worse function than either the middle (P¼ 0.03) or
high (P¼ 0.05) compliant group (Table V). There was no ef-
fect of exercise compliance on function in the GH/CS group
(P¼ 0.18). However, exercise compliance had a positive
effect on pain in the GH/CS group (P¼ 0.04). GH/CS partic-
ipants who showed higher compliance had lower mean
levels of pain (4.2 0.9) compared to those with low compli-
ance (7.4 0.9).
Table IIIA
Pill compliance by visit and group. A compliant participant was de-
fined as being in the top compliance group (85e100%) during both
Phase I (months 0e6) and Phase II (months 7e12) of the study
Group 6-Month (%) 12-Month (%) Compliant N (%)
GH/CS 0e84.9 0e84.9 No 11 (26)
0e84.9 85e100 No 0 (0)
85e100 0e84.9 No 4 (9)
85e100 85e100 Yes 28 (65)
Placebo 0e84.9 0e84.9 No 13 (31)
0e84.9 85e100 No 3 (7)
85e100 0e84.9 No 3 (7)
85e100 85e100 Yes 23 (55)
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Pill compliance had no effect on 6-min walk distance at
6-month follow-up for either group (Table IV). However, at
12 months, the compliant GH/CS group walked signiﬁcantly
further on average than the non-compliant group (429.4 m
vs 383.8 m, P¼ 0.01). This effect was not apparent in the
placebo group (P¼ 0.23) (Table IV).
The low exercise-compliant placebo group had poorer
mobility (i.e., walked a signiﬁcantly shorter distance) than
the high (P¼ 0.003) compliant group. Exercise compliance
had no statistically signiﬁcant effect on mobility in the GH/
CS group (P¼ 0.07) (Table V).
Strength
There were no signiﬁcant effects of pill compliance in
either the GH/CS or placebo group (Table IV).
The high exercise-compliant GH/CS group was signiﬁ-
cantly stronger in knee extension strength (mean¼ 267.4 N)
compared to the middle (mean¼ 182.9 N, P¼ 0.01) and low
(mean¼ 160.7 N, P¼ 0.002) compliant groups (Table V).
Table IIIB
Exercise compliance groups for Phase II (months 7e12). There
was no difference in distribution of compliance between the groups
Group 12-Month (%) N (%)
GH/CS 0e69.9 13 (34)
70e84.9 12 (32)
85e100 13 (34)
Placebo 0e69.9 14 (38)
70e84.9 8 (22)
85e100 15 (41)There was no difference in extension strength in the placebo
group (P¼ 0.15). Moreover, exercise compliance had no
effect on knee ﬂexion strength.
Balance
There were no positive effects of better pill compliance on
mean balance. The only signiﬁcant effect of pill compliance
on mean balance occurred at 6-month follow-up in which
the non-compliant GH/CS group had better balance than
the compliant cohort (P¼ 0.05) (Table IV).
There was no statistically signiﬁcant exercise compliance
effect on mean balance for either group.
Discussion
Two long-term studies showed signiﬁcant improvements
in self-reported physical function and signiﬁcantly less dis-
ease progression after 3 years of treatment with glucos-
amine sulfate2,9. Michel et al.30 recently showed no joint
space loss after 2 years of treatment with CS, but no signif-
icant difference in pain and function relative to a placebo.
Several meta-analyses concluded that glucosamine and
chondroitin reduce pain and may have considerable utility
in OA treatment5e8.
At the conclusion of Phase I, both groups had improved
function by 8%. After 12 months, glucosamine/chondroitin
combined with exercise for the ﬁnal 6 months resulted in
a 17% improvement from baseline compared to 12% for
the placebo group. Despite using appropriate randomiza-
tion techniques, there was approximately a 20% difference
in mean function at baseline. The use of covariance helped
to adjust statistically for this difference, but did not account
for all of the variance. The lower functional level of the GH/Table IV
Within group (GH/CS or placebo) effects of pill compliance at 6- (Phase I) and 12-month (Phase II) follow-up on function, pain, 6-min walk,
knee strength, and balance (meanþSE)
Outcome Group Compliant* N 6-Monthy P6-month 12-Monthy P12-month
Function GH/CS No 14 20.2 (1.9) 0.64 21.3 (2.0) 0.06
Yes 28 21.2 (1.4) 16.9 (1.4)
Placebo No 17 22.1 (1.7) 0.91 20.3 (1.8) 0.72
Yes 23 22.3 (1.5) 19.4 (1.5)
Pain GH/CS No 14 5.6 (0.7) 0.60 7.3 (0.8) 0.02
Yes 28 6.0 (0.5) 4.9 (0.6)
Placebo No 17 5.6 (0.6) 0.46 5.1 (0.8) 0.71
Yes 23 6.2 (0.5) 4.7 (0.6)
6-min walk (m) GH/CS No 15 389.5 (14.0) 0.50 383.8 (14.7) 0.01
Yes 28 406.3 (9.8) 429.4 (10.3)
Placebo No 19 396.1 (11.7) 0.57 404.6 (12.4) 0.23
Yes 23 405.2 (11.0) 425.0 (11.5)
Knee extension
strength (N)
GH/CS No 8 156.8 (28.9) 0.52 200.2 (24.7) 0.86
Yes 21 179.3 (18.1) 205.3 (15.6)
Placebo No 8 165.8 (28.7) 0.70 184.2 (24.5) 0.28
Yes 17 214.4 (19.9) 216.2 (17.1)
Knee ﬂexion
strength (N)
GH/CS No 8 96.9 (13.1) 0.69 98.7 (14.1) 0.97
Yes 21 103.2 (8.3) 98.1 (8.9)
Placebo No 8 94.8 (13.1) 0.48 115.7 (14.0) 0.67
Yes 17 106.1 (9.1) 122.9 (9.7)
Balance
(foot length)
GH/CS No 6 0.57 (0.03) 0.05 0.56 (0.03) 0.40
Yes 19 0.50 (0.02) 0.52 (0.02)
Placebo No 5 0.54 (0.03) 0.17 0.56 (0.04) 0.52
Yes 15 0.58 (0.02) 0.59 (0.02)
*A compliant participant was deﬁned as being in the top compliance group (85e100%) during both Phase I (months 0e6) and Phase II
(months 7e12) of the study. yAdjusted for baseline, age and BMI.
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Within group (GH/CS or placebo) effects of exercise compliance on pain, function, 6-min walk, balance, and extension and flexion knee
strength (meanþSE). Compliance was divided into high, middle, and low groups
Outcome Group Compliance tertile* N 12-Monthy P12-monthz
Function GH/CS Low 13 19.1 (2.1) 0.18
Middle 12 19.7 (2.2)
High 13 14.6 (2.1)
Placebo
Low 13 23.7 (2.1) 0.05
Middle 8 16.4 (2.6)
High 15 18.0 (2.0)
Pain GH/CS Low 13 7.4 (0.9) 0.04
Middle 12 5.4 (1.0)
High 13 4.2 (0.9)
Placebo Low 13 5.9 (0.9) 0.33
Middle 8 3.8 (1.2)
High 15 4.4 (0.9)
6-min walk (m) GH/CS Low 13 405.5 (14.5) 0.07
Middle 12 453.8 (15.2)
High 13 435.0 (14.3)
Placebo Low 14 395.1 (13.9) 0.01
Middle 8 422.9 (18.7)
High 15 454.5 (13.5)
Knee extension strength (N) GH/CS Low 8 160.7 (24.3) 0.003
Middle 10 182.9 (22.0)
High 10 267.4 (21.8)
Placebo Low 7 166.3 (25.5) 0.15
Middle 6 217.3 (28.2)
High 9 232.7 (22.5)
Knee ﬂexion strength (N) GH/CS Low 8 82.7 (15.9) 0.38
Middle 10 105.4 (14.5)
High 10 110.5 (14.4)
Placebo Low 7 116.4 (16.6) 0.83
Middle 6 127.6 (18.3)
High 9 113.8 (14.8)
Balance (foot length) GH/CS Low 6 0.55 (0.04) 0.27
Middle 8 0.52 (0.03)
High 10 0.59 (0.03)
Placebo Low 4 0.53 (0.04) 0.29
Middle 6 0.61 (0.04)
High 7 0.61 (0.03)
*Compliance groups: low¼ 0e68.3%, middle¼ 69.2e86.9%, and high¼ 87.2e100%. yAdjusted for baseline, age and BMI. zThe 12-month
P-value is an overall comparison between the three groups. When an overall P-value was signiﬁcant, pairwise comparisons were made
(see text for details).CS group at baseline contributed to the large percentage
improvement in function without signiﬁcant between group
differences. Based on the OMERACTeOARSI (Outcome
measurements in rheumatologyeosteoarthritis research so-
ciety international) set of responder criteria31 (improvement
in both pain and function of 20%) the GH/CS group
showed no clinically important response during Phase I
(pill only) or Phase II (pill plus exercise).
Power calculations indicated that we had 80% power to
detect an 8.2% difference in mean 6-min walk distance
and a 4.6-unit difference in mean WOMAC function (range
0e68) between groups after 12 months. In the ADAPT
study, we noted a 5-unit (24%) difference in mean WOMAC
function between the healthy lifestyle control group and the
exercise plus weight loss group that was statistically and
clinically signiﬁcant22. However, in the present study, after
12 months, there was only a 1.2-unit difference betweenthe means of the two groups. Although our study was ade-
quately powered to detect small clinically signiﬁcant differ-
ences, these differences were too small to be detectable
and of little clinical interest.
Mean pain scores did not differ between the groups over
time; however, there was a threefold reduction in the num-
ber of participants who used rescue medication (i.e., acet-
aminophen) in the GH/CS group compared to the placebo
group. Recent evidence from GAIT, a Phase III clinical trial,
also found no difference in overall WOMAC pain scores af-
ter 24 weeks of receiving either GH, CS, glucosamine plus
chondroitin, celecoxib, or a placebo10. Clegg et al.10 found
a beneﬁcial effect of the combination of glucosamine and
chondroitin in a subset analysis of participants with moder-
ate to severe pain. The mild to moderate pain level in our
patient population may have contributed to the absence of
signiﬁcant group differences. One of the surprising results
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mately 60% in pain. In contrast, our placebo group only
had a slight increase in mean pain at 6-month follow-up rel-
ative to baseline, from 5.9 to 6.2. Nevertheless, the im-
provement in the GH/CS group was not sufﬁcient to elicit
a signiﬁcant between-group difference.
Both groups made signiﬁcant gains in mobility over time
(Table II). The addition of exercise to both groups appeared
to affect performance similarly. The 6-month follow-up data
from the ADAPT trial showed a 9.6% improvement in 6-min
walk distance in the exercise only group22, who attended
exercise sessions three times per week at the center. The
5e6% improvement in mobility in the GATES cohort may
have been due, in part, to a twice per week rather than
a three times per week center-based exercise protocol.
The placebo group made clinically signiﬁcant gains in
mean knee ﬂexion strength from baseline, 23.7 N and
41.8 N during each phase of the study, respectively (Table
II). Strength in the GH/CS group, however, remained close
to baseline values after 12 months of GH/CS therapy that
included 6 months of exercise. Overall, glucosamine/chon-
droitin therapy, either alone or with exercise, had no effect
on knee strength.
Balance data indicated that the placebo group signiﬁ-
cantly improved relative to the GH/CS group at both 6-
and 12-month follow-ups. The placebo group improved
balance approximately 10% at 6 months and an additional
2% after 6 months of exercise. While the differences
between the groups were statistically different, whether
a 10% change in balance in clinically relevant is debatable
(Table II).
The lack of a deﬁnitive treatment effect with oral glucos-
amine or chondroitin across studies may also be related to
its low bioavailability. Bioavailability is the percentage of
drug that enters the blood stream and is available for met-
abolic use in target tissues (e.g., the joint tissues). Values
for acetaminophen and NSAIDs range between 80% and
100%; hence, all or most of these drugs reach the targeted
tissues. Oral glucosamine is generally reported as having
a bioavailability of approximately 5%32,33. Setnikar et al.34
suggested that glucosamine is broken down in the diges-
tive tract, excreted as either carbon dioxide or urea, and
readily absorbed by the liver and kidneys. Therefore, only
a low percentage of the drug ingested may actually reach
the target tissues and evoke metabolic changes in the artic-
ular cartilage. Recent evidence provides a slightly more
optimistic view. Using a once daily oral administration pro-
tocol for 3 consecutive days, Persiani et al.35 estimated that
the bioavailability of glucosamine in humans after chronic
dosing resulted in maximum plasma concentration levels
at steady state (Cmax) that were higher than previously
reported with acute dosing in animal studies. In two unpub-
lished studies, they found similar plasma and synovial ﬂuid
concentrations of glucosamine after 14 consecutive days of
a regimen of 1500 mg of glucosamine sulfate once-daily,
and 27% bioavailability in rats after therapeutic doses of
glucosamine sulfate equivalent to 2000 mg for a 65-kg
man36,37.
A potential limitation of the present study was the use of
GH. The majority of positive trials has used glucosamine
sulfate, not GH; however, to our knowledge there is no di-
rect comparison of the two preparations in human trials to
determine if one form is superior to the other. The two prod-
ucts release free glucosamine with glucosamine sulfate re-
leasing a relatively small amount of sulfate (250 mg) relative
to the 4.5 g found in normal diets7,38,39. Hoffer et al.40 found
that there was a signiﬁcant 14% increase in serum sulfateconcentrations 3 h after a 1-g dose of glucosamine sulfate.
It is not known if the additional release of sulfate would pro-
vide a therapeutic beneﬁt signiﬁcant enough to result in dif-
ferences in efﬁcacy.
Oral chondroitin may also have difﬁculty in reaching the
joint tissues. In one study testing GH/CS in dogs, the bio-
availability of CS was only 4.9% after a single dose, but
showed signiﬁcant accumulation after 7 consecutive days
with over a 200% bioavailability41. Providing a single dose
to an equine model, Du et al.32 showed a higher bioavail-
ability of low vs high-molecular-weight CS. Cho et al.42 sug-
gested that low-molecular-weight CS is more easily
absorbed by the intestinal lining. Baici et al.43 tested oral
CS on healthy and arthritic participants and showed that
glycosaminoglycan levels in the serum did not signiﬁcantly
change after a single dose. Taken together, these results
suggest that a single dose of oral CS may not beneﬁt joint
tissues but multiple doses may make chondroitin more bio-
available. Clearly, further studies are needed to determine
the actual amounts that reach joint tissues with chronic dos-
ing and the amounts needed in the tissue to achieve a bio-
logic effect.
The possibility that the pain-reducing effects seen in
previous studies are due to gastrointestinal and soft tis-
sue absorption of glucosamine and chondroitin instead
of biologic effects on joint tissues has also been sug-
gested by previous investigators. Laverty et al.33 and Lip-
piello et al.44 suggested that the beneﬁcial effects of
glucosamine and chondroitin could be due to an overall
analgesic effect from absorption in soft tissues, especially
in the gastrointestinal track, where extensive ﬁrst-pass
metabolism is evident32, and not from improvements to
the articular cartilage or other joint tissues. The exact
mechanism for this effect is not known but is under
investigation.
Three long-term RCTs that demonstrated positive results
with either glucosamine sulfate or CS used a once-daily
medication regimen2,9,30. Peak levels of glucosamine occur
2e3 h after ingestion and a 1500-mg dosage provides
greater plasma levels of glucosamine than a 750-mg dos-
age35. Overall, these studies suggest that a once-daily dos-
age of 1500 mg of glucosamine may be more efﬁcacious
than other regimens, including the 1500-mg daily regimen
used in our study in which participants had the option of
once-daily or thrice daily (3 500/400 mg) routines.
To determine if there was a dose response to pill
compliance, we divided each group into compliant and
non-compliant participants. A compliant participant was de-
ﬁned as being in the top compliance group (85e100%)
during the ﬁrst and second 6 months of the study. The
pill-compliant GH/CS group showed signiﬁcantly reduced
pain and higher mobility relative to the non-compliant
GH/CS group. This trend was not evident in the placebo
group.
A strong exercise compliance effect on function and mo-
bility was more apparent in the placebo group, while the
high exercise-compliant GH/CS group showed signiﬁcant
improvement in knee extension strength. Hence, high pill
compliance tended to be more beneﬁcial for the GH/CS
group while high exercise compliance appeared to have
some beneﬁt for both groups.
Additional design modiﬁcations for future studies should
include a once-daily dosage regimen, the use of glucosamine
sulfate instead of GH, quantitative or semi-quantitative mag-
netic resonance imaging (MRI) to document cartilage volume
and joint structure45,46, and a 2 2-factorial design to study
the beneﬁts of glucosamine and chondroitin combined with
1265Osteoarthritis and Cartilage Vol. 15, No. 11exercise. Since our study indicated that pill compliance may
be critical to the success of the intervention, we recommend
that intensive patient education be part of any intervention
involving these supplements/drugs. We also agree with
Clegg et al.10 that further work regarding the pharmokinetics
of glucosamine and chondroitin is required.
Glucosamine and chondroitin have gained wide popular-
ity as alternative treatments for OA. This preliminary study
was the ﬁrst designed to examine the effects of these pre-
scription drugs/nutraceuticals in combination with exercise.
The GH/CS group was not superior to the placebo group in
function, pain, or mobility after both phases of the interven-
tion (pill only and pill plus exercise). Post hoc analysis
showed that more pill-compliant participants in the GH/CS
group had greater improvements in pain and mobility than
less compliant participants; however, caution should be
used in interpreting these preliminary data.
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